In the latest look at conflicts of interest in science, a new analysis found 15% of the authors of editorials accompanying studies in prestigious medical journals about heart drugs and devices had financial ties to the companies that sponsored the clinical trials, but they did not disclose the relationships.
Generally, financial ties between study authors and manufacturers have generated considerable interest due to concerns over influencing medical research and practice. But this latest analysis, which was published in JAMA Internal Medicine, extends this unease to editorial writers, who are also in a position to sway thinking about trial results.
Create a display name to comment
This name will appear with your comment